

N-Sulfonyloxy carbamates as reoxidants for aminohydroxylation reactions



David J. Klauber, Timothy J. Donohoe, Majid J. Chughtai
and Andrew D. Campbell[‡]




Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK.

[‡]AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK.

Introduction

The Sharpless asymmetric aminohydroxylation (AA) reaction is a powerful method for the synthesis of enantioenriched *syn*-1,2-amino alcohols from alkenes (**Scheme 1**).^{1,2}




Scheme 1 – Reagents & conditions: *t*BuOCl (3.05 eq.), NaOH (3.05 eq.), K₂[OsO₂(OH)₄] (4 mol%), (i) BocNH₂ (3.10 eq.), (DHQ)₂PHAL (6 mol%), *n*PrOH:H₂O (2:1), 0 °C; (ii) TeocNH₂ (3.10 eq.), (DHQ)₂PHAL (5 mol%), *n*PrOH:H₂O (1:1).

This methodology has two principal drawbacks: (i) poor regioselectivity with some unsymmetrical alkenes; (ii) requirement of 3 equivalents of nitrogen source to obtain satisfactory product yields.

The Donohoe group has made efforts to address both of these issues:

(i) **Tethered Aminohydroxylation (TA)** – allows for complete regiocontrol and high diastereoselectivity with chiral alcohols (**Scheme 2**).³




Scheme 2 – Reagents & conditions: *t*BuOCl (1.00 eq.), NaOH (0.92 eq.), K₂[OsO₂(OH)₄] (4 mol%), *i*Pr₂NEt (5 mol%), *n*PrOH:H₂O (1:1).

The reaction is limited by modest yields and largely confined to allylic alcohols, homoallylic substrates afford poor product yields (<40%).

(ii) **Novel reoxidants** – this project examined alternative leaving groups on nitrogen in the nitrene equivalent reoxidant.

N-Sulfonyloxy carbamate reoxidants


It was found that *N*-chlorocarbamates have a limited lifetime in aminohydroxylation reactions; this cannot be compensated for by use of excess reagent in the intramolecular TA reaction. In some TA substrates, competing chlorination of the alkene was observed as a detrimental side reaction.



Scheme 3 – Reagents & conditions: (i) CDI (1.50 eq.), MeCN, then imidazole (4.00 eq.), NH₂OH.HCl (5.00 eq.); (ii) MesSO₂Cl (1.00 eq.), Et₃N (1.00 eq.), toluene:DMF (4:1), 0 °C.

N-Sulfonyloxy carbamates have been developed as superior reoxidants for the TA reaction.⁴ These were readily prepared in good yields in a two-pot procedure by sequential reaction of the corresponding alcohol with CDI and hydroxylamine, followed by sulfonylation (**Scheme 3**).


The modified procedure removes the need for both base and chlorinating agent and allows lower catalyst loading. Use of stoichiometric potassium osmate allowed isolation of the intermediate osmium azaglycolate **1**, providing strong evidence for oxidation of Os (VI) by the *N*-sulfonyloxy carbamate, and *syn*-addition across the double bond (**Scheme 4**).



Scheme 4 – Reagents & conditions: (i) K₂[OsO₂(OH)₄] (*i*Pr₂NEt (5 mol%), *n*PrOH:H₂O (1:1)); (ii) K₂[OsO₂(OH)₄] (1.00 eq.), TMEDA (1.00 eq.), *n*PrOH.

Allylic systems


In all tested cases, yields of the oxazolidinones were higher than with the previously reported procedure (**Scheme 5**).



Scheme 5 – Reagents & conditions: (i) K₂[OsO₂(OH)₄], *i*Pr₂NEt (5 mol%), *n*PrOH:H₂O (1:1).

Homoallylic systems


A slower reaction to form 6-membered oxazinones meant that homoallylic substrates were particularly susceptible to alkene chlorination. The new procedure shows more marked improvement than the allylic series (**Scheme 6**).



Scheme 6 – Reagents & conditions: (i) K₂[OsO₂(OH)₄], *i*Pr₂NEt (5 mol%), *n*PrOH:H₂O (1:1).

Intermolecular aminohydroxylations

N-Sulfonyloxy carbamates give poor regio- and enantioselectivities compared with conventional AA procedures, due to their incompatibility with hydroxide bases. However, ester-based leaving groups allow comparable selectivities and yields to be obtained using half the quantity of nitrogen source. The 2,4,6-trichlorobenzoyl derivative was found to be optimal (**Scheme 7**).



Scheme 7 – Reagents & conditions: K₂[OsO₂(OH)₄] (4 mol%), LiOH (1.32 eq.) (i) P-Boc - (DHQ)₂PHAL (6 mol%), *n*PrOH:H₂O (2:1), 0 °C; (ii) P-Teoc - (DHQ)₂PHAL (5 mol%), *n*PrOH:H₂O (1:1).

Acknowledgements

We thank AstraZeneca for financial support and Rhian Thomas and Farrah Bhatti for crystallographic analysis.

References

- Reddy, K. L.; Sharpless, K. B., *J. Am. Chem. Soc.* **1998**, 120, 1207.
- Reddy, K. L.; Dress, K. R.; Sharpless, K. B., *Tett. Lett.* **1998**, 39, 3667.
- Donohoe, T. J.; Johnson, P. D.; Pye, R. J.; Keenan, M., *Org. Lett.* **2004**, 6, 2583.
- Donohoe, T. J.; Chughtai, M. J.; Klauber, D. J.; Griffin, D.; Campbell, A. D., *J. Am. Chem. Soc.* **2006**, 128, 2514